Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

CMS Reimbursement Change For Hyaluronic Acid-Based Viscosupplement Products

Fidia is committed to compliantly assisting our customers to ensure a smooth transition from WAC-based to ASP-based reimbursement.  The ASP file, the basis for setting reimbursement, becomes effective July 1, 2022.  Read the full communication sent to customers of Fidia Pharma USA Inc. and learn how to contact us for more information and assistance.

Our Products

Hymovis

The industry’s only 2-injection hyaluronic acid treatment for osteoarthritis (OA) knee pain

Triluron

A 3-injection hyaluronic acid treatment for osteoarthritis (OA) knee pain

Hyalgan

The original safe, proven hyaluronic acid treatment for osteoarthritis (OA) knee pain

NuDYN

An acellular, shelf-stable, amniotic membrane-derived injectable allograft, which retains rich intrinsic beneficial properties of the amniotic membrane

Richplat Ortho

NEW from Fidia Pharma USA Inc. Quality, consistency, and reliability—all in one cost-effective PRP system

HyaloGyn

Hyaluronic acid-based gel and suppositories that provide temporary relief of vaginal dryness symptoms

Recent Company News

  • Upcoming Reimbursement Changes
    On November 2, 2021, The Centers for Medicare & Medicaid Services (CMS) issued their Final Rule on reporting Average Sales Price (ASP) for items, services, supplies and products that are reimbursable as drugs or biologics under a variety of Medicare Part B provisions.
    Read More
  • Letter to Healthcare Providers
    Regarding upcoming CMS reimbursement changes
    Read More
  • Fidia Celebrates Its 75th Anniversary
    Every day we proudly celebrate the foresight and expertise of those who have helped to build the company, and recognize the vision of those who are already shaping tomorrow’s world.
    Read More

Are you sure you want to navigate away from this page?

Click OK to continue or Cancel to stay on current page.